WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562386
CAS#: 38183-03-8
Description: 7,8-Dihydroxyflavone is an agonist of tyrosine receptor kinase B (TrkB). It acts by promoting immature neuron survival after TBI through activation of the BDNF signaling pathway.
Hodoodo Cat#: H562386
Name: 7,8-Dihydroxyflavone
CAS#: 38183-03-8
Chemical Formula: C15H10O4
Exact Mass: 254.06
Molecular Weight: 0.000
Elemental Analysis: Chemical Formula: C15H10O4 Exact Mass: 254.0579 Molecular Weight: 254.2410 Elemental Analysis: C, 70.86; H, 3.96; O, 25.17
Synonym: 7,8-Dihydroxyflavone; DHF; 7,8-DHF;
IUPAC/Chemical Name: 7,8-Dihydroxy-2-phenyl-chromen-4-one
InChi Key: COCYGNDCWFKTMF-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H10O4/c16-11-7-6-10-12(17)8-13(19-15(10)14(11)18)9-4-2-1-3-5-9/h1-8,16,18H
SMILES Code: O=C1C=C(C2=CC=CC=C2)OC3=C1C=CC(O)=C3O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Wurzelmann M, Romeika J, Sun D. Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. Neural Regen Res. 2017 Jan;12(1):7-12. doi: 10.4103/1673-5374.198964. Review. PubMed PMID: 28250730; PubMed Central PMCID: PMC5319242.
2: Du X, Hill RA. The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia. J Mol Neurosci. 2016 Nov;60(3):336-348. Epub 2016 Aug 15. Review. PubMed PMID: 27525638.
3: Zhang JC, Yao W, Hashimoto K. Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. Curr Neuropharmacol. 2016;14(7):721-31. Review. PubMed PMID: 26786147; PubMed Central PMCID: PMC5050398.
4: Liu C, Chan CB, Ye K. 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders. Transl Neurodegener. 2016 Jan 6;5:2. doi: 10.1186/s40035-015-0048-7. eCollection 2016. Review. PubMed PMID: 26740873; PubMed Central PMCID: PMC4702337.
5: Moosavi F, Hosseini R, Saso L, Firuzi O. Modulation of neurotrophic signaling pathways by polyphenols. Drug Des Devel Ther. 2015 Dec 21;10:23-42. doi: 10.2147/DDDT.S96936. eCollection 2016. Review. PubMed PMID: 26730179; PubMed Central PMCID: PMC4694682.
6: Du X, Hill RA. 7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders. Neurochem Int. 2015 Oct;89:170-80. doi: 10.1016/j.neuint.2015.07.021. Epub 2015 Jul 26. Review. PubMed PMID: 26220903.
7: Ragen BJ, Seidel J, Chollak C, Pietrzak RH, Neumeister A. Investigational drugs under development for the treatment of PTSD. Expert Opin Investig Drugs. 2015 May;24(5):659-72. doi: 10.1517/13543784.2015.1020109. Epub 2015 Mar 14. Review. PubMed PMID: 25773140.
8: Zeng Y, Wang X, Wang Q, Liu S, Hu X, McClintock SM. Small molecules activating TrkB receptor for treating a variety of CNS disorders. CNS Neurol Disord Drug Targets. 2013 Nov;12(7):1066-77. Review. PubMed PMID: 23844685.
9: Obianyo O, Ye K. Novel small molecule activators of the Trk family of receptor tyrosine kinases. Biochim Biophys Acta. 2013 Oct;1834(10):2213-8. doi: 10.1016/j.bbapap.2012.08.021. Epub 2012 Sep 6. Review. PubMed PMID: 22982231; PubMed Central PMCID: PMC3602283.
10: Andero R, Ressler KJ. Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav. 2012 Jul;11(5):503-12. doi: 10.1111/j.1601-183X.2012.00801.x. Epub 2012 May 11. Review. PubMed PMID: 22530815; PubMed Central PMCID: PMC3389160.